|
US7000A
(en)
*
|
|
1850-01-08 |
|
Smut-machine |
|
CU22545A1
(es)
|
1994-11-18 |
1999-03-31 |
Centro Inmunologia Molecular |
Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
|
|
US5700466A
(en)
|
1981-09-08 |
1997-12-23 |
The Rockefeller University |
Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
|
|
US5672347A
(en)
|
1984-07-05 |
1997-09-30 |
Genentech, Inc. |
Tumor necrosis factor antagonists and their use
|
|
US4677063A
(en)
|
1985-05-02 |
1987-06-30 |
Cetus Corporation |
Human tumor necrosis factor
|
|
IL73883A
(en)
|
1984-12-20 |
1990-12-23 |
Yeda Res & Dev |
Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
|
|
US5120712A
(en)
|
1986-05-05 |
1992-06-09 |
The General Hospital Corporation |
Insulinotropic hormone
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
US5183657A
(en)
|
1988-03-11 |
1993-02-02 |
Celltech Limited |
Antibodies for use in antilymphocyte antibody therapy
|
|
US5359037A
(en)
|
1988-09-12 |
1994-10-25 |
Yeda Research And Development Co. Ltd. |
Antibodies to TNF binding protein I
|
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
|
US5360716A
(en)
|
1988-10-24 |
1994-11-01 |
Otsuka Pharmaceutical Co., Ltd. |
Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
|
|
ES2052027T5
(es)
|
1988-11-11 |
2005-04-16 |
Medical Research Council |
Clonacion de secuencias de dominio variable de inmunoglobulina.
|
|
US5223395A
(en)
|
1988-12-01 |
1993-06-29 |
Centocor, Inc. |
Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
|
US6262239B1
(en)
|
1989-05-18 |
2001-07-17 |
Yeda Research And Development Co., Ltd. |
TNF receptor-specific antibodies
|
|
US6232446B1
(en)
|
1989-05-18 |
2001-05-15 |
Yeda Research And Development Co. Ltd. |
TNF ligands
|
|
US5959087A
(en)
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
|
US20030225254A1
(en)
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
|
US6498237B2
(en)
|
1989-08-07 |
2002-12-24 |
Peptech Limited |
Tumor necrosis factor antibodies
|
|
US6315999B1
(en)
|
1989-08-10 |
2001-11-13 |
Solvay, S.A. |
Pharmaceutical product for the treatment of sepsis
|
|
JPH05501351A
(ja)
|
1989-08-16 |
1993-03-18 |
カイロン コーポレイション |
プロホルモンタンパク質に対する開裂部位阻止抗体及びその使用
|
|
NZ235148A
(en)
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
|
DE59010908D1
(de)
|
1989-09-12 |
2000-08-10 |
Hoffmann La Roche |
TNF-bindende Proteine
|
|
US20040010810A1
(en)
|
1990-01-12 |
2004-01-15 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5459061A
(en)
|
1990-01-26 |
1995-10-17 |
W. Alton Jones Cell Science Center, Inc. |
Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
|
|
US7253264B1
(en)
|
1990-06-28 |
2007-08-07 |
Sanofi-Arentideutschland GmbH |
Immunoglobulin fusion proteins, their production and use
|
|
US6916605B1
(en)
|
1990-07-10 |
2005-07-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
US5726152A
(en)
|
1990-09-21 |
1998-03-10 |
Merck & Co., Inc. |
Vascular endothelial cell growth factor II
|
|
US5958413A
(en)
|
1990-11-01 |
1999-09-28 |
Celltech Limited |
Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
|
|
GB9109645D0
(en)
|
1991-05-03 |
1991-06-26 |
Celltech Ltd |
Recombinant antibodies
|
|
SK281143B6
(sk)
|
1991-03-06 |
2000-12-11 |
Merck Patent Gesellschaft Mit Beschr�Nkter Haftung |
Chimérická monoklonálna protilátka, expresné vektory a farmaceutický prostriedok
|
|
US6284471B1
(en)
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
|
OA10149A
(en)
|
1991-03-29 |
1996-12-18 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists
|
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
|
US5582998A
(en)
|
1991-06-19 |
1996-12-10 |
Boehringer Ingelheim International Gmbh |
Monoclonal antibodies against human TNF-binding protein I (TNF-BP I) and immunoassays therefor
|
|
WO1993000917A1
(en)
|
1991-07-05 |
1993-01-21 |
Seragen, Inc. |
Epidermal growth factor receptor targeted molecules for treatment of inflammatory arthritis
|
|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
GB9225448D0
(en)
|
1992-12-04 |
1993-01-27 |
Erba Carlo Spa |
Improved synthesis of polymer bioactive conjugates
|
|
US5888511A
(en)
|
1993-02-26 |
1999-03-30 |
Advanced Biotherapy Concepts, Inc. |
Treatment of autoimmune diseases, including AIDS
|
|
EP0614984B2
(en)
|
1993-03-05 |
2010-11-03 |
Bayer HealthCare LLC |
Anti-TNF alpha human monoclonal antibodies
|
|
US6090385A
(en)
|
1993-12-10 |
2000-07-18 |
Maes; Hubert |
Method of treating cancer
|
|
CA2139385C
(en)
|
1994-02-04 |
2001-12-25 |
Gottfried Alber |
Products containing g-csf and tnf binding protein
|
|
IL112372A
(en)
|
1994-02-07 |
2001-08-26 |
Res Dev Foundation |
Non-viral vector for the delivery of genetic information to cells
|
|
US6579697B1
(en)
|
1995-05-11 |
2003-06-17 |
Yeda Research And Development Co. Ltd. |
Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
|
|
GB9410533D0
(en)
|
1994-05-26 |
1994-07-13 |
Lynxvale Ltd |
In situ hybridisation and immuno-Chemical localisation of a growth factor
|
|
ES2167391T3
(es)
|
1994-09-16 |
2002-05-16 |
Merck Patent Gmbh |
Inmunoconjugados ii.
|
|
DE4446471C2
(de)
|
1994-12-23 |
1997-05-22 |
Fraunhofer Ges Forschung |
Verfahren zur Montage eines Chips auf einem flexiblen Schaltungsträger
|
|
US5928939A
(en)
|
1995-03-01 |
1999-07-27 |
Ludwig Institute For Cancer Research |
Vascular endothelial growth factor-b and dna coding therefor
|
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
|
US6020473A
(en)
|
1995-08-25 |
2000-02-01 |
Genentech, Inc. |
Nucleic acids encoding variants of vascular endothelial cell growth factor
|
|
WO1997014719A1
(en)
|
1995-10-16 |
1997-04-24 |
Unilever N.V. |
A bifunctional or bivalent antibody fragment analogue
|
|
US5747532A
(en)
|
1995-11-21 |
1998-05-05 |
Medinox, Inc. |
Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
|
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
HU230048B1
(hu)
|
1996-02-09 |
2015-06-29 |
Abbvie Biotechnology Ltd |
Humán TNFalfa-kötő antitestek alkalmazása
|
|
US5664034A
(en)
|
1996-05-21 |
1997-09-02 |
Lucent Technologies Inc. |
Lightwave communication monitoring switch
|
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
|
US6013780A
(en)
|
1996-09-06 |
2000-01-11 |
Technion Research & Development Co. Ltd. |
VEGF145 expression vectors
|
|
US6750044B1
(en)
|
1996-10-17 |
2004-06-15 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
|
|
US20030165467A1
(en)
|
1997-01-21 |
2003-09-04 |
Technion Research & Development Co., Ltd. |
Angiogenic factor and use thereof in treating cardiovascular disease
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
US6485942B1
(en)
|
1997-02-14 |
2002-11-26 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US6172213B1
(en)
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
|
US6777534B1
(en)
|
1997-12-09 |
2004-08-17 |
Children's Medical Center Corporation |
Peptide antagonists of vascular endothelial growth factor
|
|
US20020192211A1
(en)
|
1998-03-17 |
2002-12-19 |
Hudziak Robert M. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
US20030224001A1
(en)
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
|
US20030175271A1
(en)
|
1998-05-20 |
2003-09-18 |
Kyowa Hakko Kogyo Co., Ltd. |
VEGF activity inhibitor
|
|
US7264801B2
(en)
|
1998-08-11 |
2007-09-04 |
Genentech, Inc. |
EG-VEGF nucleic acids and polypeptides and method of use
|
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6136599A
(en)
|
1998-12-10 |
2000-10-24 |
Bayer Corporation |
Human hybrid host cell for mammalian gene expression
|
|
EP2016953A3
(en)
|
1998-12-22 |
2009-04-15 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists and uses thereof
|
|
EP1022027A1
(en)
|
1999-01-22 |
2000-07-26 |
Applied Research Systems ARS Holding N.V. |
Tumor necrosis factor antagonists and their use in endometriosis
|
|
US6379666B1
(en)
|
1999-02-24 |
2002-04-30 |
Edward L. Tobinick |
TNF inhibitors for the treatment of neurological, retinal and muscular disorders
|
|
IL145941A
(en)
|
1999-04-28 |
2007-08-19 |
Univ Texas |
Compositions and methods for cancer treatment by selectively inhibiting vegf
|
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
|
US7049410B2
(en)
|
1999-05-14 |
2006-05-23 |
Majumdar Adhip P N |
Antibodies to a novel EGF-receptor related protein (ERRP)
|
|
EP2042194A3
(en)
|
1999-05-14 |
2009-04-22 |
Imclone Systems, Inc. |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
|
JP2003507006A
(ja)
|
1999-05-20 |
2003-02-25 |
サイオス，インコーポレーテッド |
血管内皮増殖因子改変体
|
|
US6413744B1
(en)
|
1999-08-25 |
2002-07-02 |
Immunex Corporation |
Methods and host cells for improved cell culture
|
|
AU2001239884B2
(en)
|
2000-02-25 |
2006-08-10 |
Vegenics Limited |
Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
|
|
AU4445601A
(en)
|
2000-03-31 |
2001-10-08 |
Centre National De La Recherche Scientifique-Cnrs |
Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
|
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
|
US20030166524A1
(en)
|
2000-05-22 |
2003-09-04 |
John Ford |
Therapeutic uses of IL-1 receptor antagonist
|
|
AU2001264946A1
(en)
|
2000-05-24 |
2001-12-03 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
|
CA2422881A1
(en)
|
2000-10-13 |
2002-04-18 |
Uab Research Foundation |
Human anti-epidermal growth factor receptor single-chain antibodies
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
PL362324A1
(en)
|
2001-02-19 |
2004-10-18 |
Merck Patent Gmbh |
Artificial fusion proteins with reduced immunogenicity
|
|
US7667004B2
(en)
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
|
AU2002315306B2
(en)
|
2001-05-08 |
2007-05-17 |
Merck Patent Gmbh |
Combination therapy using anti-EGFR antibodies and anti-hormonal agents
|
|
WO2002100348A2
(en)
|
2001-06-13 |
2002-12-19 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (egfr)
|
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
|
US20050271663A1
(en)
|
2001-06-28 |
2005-12-08 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
|
US20040248196A1
(en)
|
2001-08-03 |
2004-12-09 |
Adams Timothy Edward |
Methods of screening based on the egf receptor crystal structure
|
|
JP4767450B2
(ja)
|
2001-08-09 |
2011-09-07 |
ポリマテック株式会社 |
コネクタおよびその製造方法
|
|
US20030226155A1
(en)
|
2001-08-30 |
2003-12-04 |
Biorexis Pharmaceutical Corporation |
Modified transferrin-antibody fusion proteins
|
|
IL161418A0
(en)
|
2001-10-15 |
2004-09-27 |
Immunomedics Inc |
Direct targeting binding proteins
|
|
JP2005289809A
(ja)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
|
US6818613B2
(en)
|
2001-11-07 |
2004-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Aqueous sustained-release formulations of proteins
|
|
US20030143603A1
(en)
|
2001-11-30 |
2003-07-31 |
Jill Giles-Komar |
Anti-TNF antibodies, compositions, methods and uses
|
|
DE10163459A1
(de)
|
2001-12-21 |
2003-07-03 |
Merck Patent Gmbh |
Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
|
|
AU2003209446B2
(en)
|
2002-03-01 |
2008-09-25 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
EP1542721A4
(en)
|
2002-06-14 |
2007-05-02 |
Centocor Inc |
MODIFIED "S" ANTIBODIES
|
|
US7696320B2
(en)
*
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
|
US20040082533A1
(en)
|
2002-08-09 |
2004-04-29 |
Kim Jong-Mook |
Electro-gene therapy of arthritis by using an expression plasmid encoding the soluble p75 tumor necrosis factor receptor-Fc fusion protein
|
|
CN104178491B
(zh)
|
2002-09-06 |
2018-07-03 |
安姆根有限公司 |
治疗性人抗-il-1r1单克隆抗体
|
|
TW200501960A
(en)
|
2002-10-02 |
2005-01-16 |
Bristol Myers Squibb Co |
Synergistic kits and compositions for treating cancer
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
US20050043233A1
(en)
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
NZ621449A
(en)
|
2003-05-30 |
2015-07-31 |
Genentech Inc |
Treatment with anti-vegf antibodies
|
|
CA2519875C
(en)
|
2003-06-06 |
2014-01-14 |
Regeneron Pharmaceuticals, Inc. |
Method of tumor regression with vegf inhibitors
|
|
US7736644B2
(en)
|
2003-06-27 |
2010-06-15 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
AR046510A1
(es)
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
US20050196340A1
(en)
|
2003-08-06 |
2005-09-08 |
Jocelyn Holash |
Use of a VEGF antagonist in combination with radiation therapy
|
|
US20050079184A1
(en)
|
2003-08-08 |
2005-04-14 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
WO2005070966A2
(en)
|
2004-01-16 |
2005-08-04 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
|
US7767792B2
(en)
|
2004-02-20 |
2010-08-03 |
Ludwig Institute For Cancer Research Ltd. |
Antibodies to EGF receptor epitope peptides
|
|
GB0521621D0
(en)
*
|
2005-10-24 |
2005-11-30 |
Domantis Ltd |
Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
|
|
US20090252681A1
(en)
|
2005-10-11 |
2009-10-08 |
Ablynx N.V. |
Nanobodies and Polypeptides Against EGFR and IGF-IR
|
|
AU2008259590A1
(en)
*
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Methods for selecting protease resistant polypeptides
|
|
GB0724331D0
(en)
*
|
2007-12-13 |
2008-01-23 |
Domantis Ltd |
Compositions for pulmonary delivery
|
|
US20100247517A1
(en)
*
|
2007-11-22 |
2010-09-30 |
Boehringer Ingelheim Internationational GmbH |
Use of mnk inhibitors for the treatment of alzheimer's disease
|
|
TW200938222A
(en)
*
|
2007-12-13 |
2009-09-16 |
Glaxo Group Ltd |
Compositions for pulmonary delivery
|